BLIS Technologies Limited, together with its subsidiaries, develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity in New Zealand, Asia Pacific, Europe Middle East and Africa, and North America. The company offers BLIS K12, an oral probiotic supplement to support ear, nose, and throat health, as well as for enhancing immunity and bad breath; BLIS M18, an oral probiotic to support teeth and gums health; and BLIS Q24, a probiotic supplement to balance the skin microbiome, restoring the health, clarity, and radiance. It provides its products in the ENT, immune, dental, and skin areas. BLIS Technologies Limited was incorporated in 2000 and is based in Dunedin, New Zealand.

Sector

Healthcare

Industry

Biotechnology

CEO

Johnson, Scott

Employees

Website

www.blis.co.nz

IPO Date

2001-07-29

Headquarters

399 Moray Place, Dunedin 9016, New Zealand

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

BLIS Technologies BLT

BLIS Technologies Earnings Call Summary

BLIS Technologies Earnings

Transcripts

Events

About BLIS Technologies Limited

BLIS Technologies
BLT